| Summary: | Introduction. Palliative care for oncological patients requires dealing with multiple disease symptoms and requires multi-drug therapy. The search for wide-spectre drugs which can affect different pathological pathways is a pressing matter.Methods. The effect of hydralazine sulfate on life quality of 63 palliative care oncological patients ECOG > 3, who stopped all specific therapy was investigated.Results. Positive correlation between hydralazine sulfate use and dose of analgetics was observed, as well as reduction of need for symptomatic therapy. The median daily use of tramadol slightly increased from 263.5 ± 4.7 to 317.2 ± 3.4 mg. In 19.4 % patients after 1 month of hydralazine sulfate therapy pain was reduced to “low” and tramadol was cancelled. Decrease in symptomatic therapy need was observed in 85 % patients.Conslusion. Use of hydralazine sulfate in palliative oncological care improves treatment and life quality.
|
|---|
